Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

10.1200/JCO.20.02060

Saved in:

Bibliographic Details
Main Authors:	Dimopoulos, Meletios A, Spicka, Ivan, Quach, Hang, Oriol, Albert, Hajek, Roman, Garg, Mamta, Beksac, Meral, Bringhen, Sara, Katodritou, Eirini, Chng, Wee-Joo, Leleu, Xavier, Iida, Shinsuke, Mateos, Maria-Victoria, Morgan, Gareth, Vorog, Alexander, Labotka, Richard, Wang, Bingxia, Palumbo, Antonio, Lonial, Sagar
Other Authors:	DEAN'S OFFICE (MEDICINE)
Format:	Article
Language:	English
Published:	AMER SOC CLINICAL ONCOLOGY 2022
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology CONTINUOUS THERAPY PLUS LENALIDOMIDE FIXED DURATION DOUBLE-BLIND OPEN-LABEL BORTEZOMIB DEXAMETHASONE OUTCOMES DARATUMUMAB PREDNISONE
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/229088
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Description
Summary:	10.1200/JCO.20.02060